All News

Alcohol use increased from 8% to 44% postpartum among pregnant people with HIV, with distinct risk factors identified for alcohol vs cannabis use.

The phase 4 study's oversampling of moderate PPD patients, showing a nearly 9-point EPDS drop by Day 15, helps close a gap left by trials that enrolled predominantly severe cases.

Roshni Koli, MD, describes how embedding mental health care within the OB/GYN setting drove high engagement and rapid symptom remission in a perinatal collaborative care study.

A large Korean birth cohort found a modest relative increase in pediatric IBD and Crohn disease risk after prenatal PPI/H2RA exposure, but absolute risk differences were under 1 case per 1000 children.

A pilot trial found nicotinamide riboside and pterostilbene cut hot flashes, bloating, and poor sleep by 50% or more in 7 days.

A recent mediation analysis shows 54% of elinzanetant's (Lynkuet) sleep benefit is independent of nighttime VMS reduction, suggesting NK1 blockade targets menopausal sleep disruption through a distinct pathway.

A retrospective study found that a tech-enabled perinatal collaborative care program delivered within an OB/GYN practice was associated with reductions in depression and anxiety symptoms.

Maegan Ashworth Dirac, MD, PhD, explains how COVID-19 infection risk and low vaccine uptake among pregnant women contributed to a rise in indirect maternal deaths worldwide.

A qualitative sub-study of the COMPASS+ Trial published in Pregnancy found that the Collaborative Care Model is well suited to obstetric settings but requires context-specific adaptation to overcome multilevel barriers.

The SELF-GYN1 trial found that at-home transvaginal ultrasonography met diagnostic quality standards in 96.2% of scans and was significantly preferred by participants over in-clinic imaging.

89.6% of women tested with Xpert Xpress MVP received appropriate treatment within 24 hours vs. 51.9% with usual care.

Kate McLean, MD, MPH, FACOG, describes how statistical clustering of more than 15,000 BV-diagnosed patients surfaced distinct microbial subtypes without predefined assumptions.

Daré Bioscience has launched Flora Sync LF5, a non-prescription vaginal probiotic capsule containing Limosilactobacillus fermentum LF5.

A cohort study of 15,382 mother-infant dyads found that subfecundity was independently associated with elevated autism spectrum disorder odds and behavioral problem scores in offspring, while IVF treatment showed no significant neurodevelopmental associations.

A new meta-analysis found that third trimester TVCL surveillance in asymptomatic women was predictive of spontaneous preterm birth.

A 12-week randomized trial found a standardized saffron extract improved mood, self-esteem, and sleep outcomes in menopausal women vs placebo.

In a phase 4 real-world study of 191 participants, zuranolone reduced EPDS scores across all baseline PPD severities by Day 15, with improvements sustained through Day 45.

A cross-sectional study published in Menopause found that while overall symptom burden was higher in women with average-age menopause, psychological and urogenital symptom scores did not differ significantly.

Kate McLean, MD, MPH, FACOG, describes how metagenomic sequencing and new transmission data are reshaping the understanding of bacterial vaginosis beyond a traditional, oversimplified definition.

A reader-driven look at the 10 most-viewed articles on Contemporary OB/GYN from the first half of 2026, spanning FDA decisions, clinical research, and emerging treatments across menopause, contraception, endometriosis, and pelvic health.

A study published in Frontiers in Public Health and led by Mount Sinai researchers found that postmenopausal women in lower-income neighborhoods experienced up to 3.8 times greater bone mineral density loss from air pollution exposure than women in wealthier areas, based on data from 9041 participants in the Women's Health Initiative.

A recap of the top-performing, most-viewed Contemporary OB/GYN stories from June 2026, including new SMFM guidance on acetaminophen in pregnancy, ACOG's break from federal vaccine recommendations, and our coverage of SLEEP 2026 in Baltimore.

Because only one third of nocturnal wakefulness during the menopausal transition is directly linked to hot flashes, VMS-targeted therapies alone are insufficient for many women with sleep disruption—and cognitive behavioral therapy for insomnia, supported by sleep society guidelines and accessible through free digital platforms, should be part of every clinician's sleep management toolkit, according to Pauline M. Maki, PhD.

A recap of the top FDA news stories covered by Contemporary OB/GYN in Q2 2026, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.

A single-center retrospective cohort study published in Pregnancy found that antibiotic administration after previable PPROM was associated with a 14.7-day increase in latency, along with higher rates of delivery beyond 22 0/7 weeks, lower intrauterine fetal demise, and improved neonatal survival to discharge.

A look ahead to the second half of 2026 for ob-gyns, including Viatris's pending FDA decision on a low-dose estrogen contraceptive patch and previews of the IDSOG, AUGS PFD Week, and The Menopause Society annual meetings.

"Given the high morbidity associated with CSEP and the increasing incidence of CSEP and PAS, patients with prior cesarean delivery should have imaging (either by a specialist familiar with the diagnosis of CSEP or a formal radiology ultrasound) as early as possible in pregnancy, when treatment is safest with the lowest risk of complications," write the authors.

Stephanie Faubion, MD, and Fiona Baker, PhD, discuss how elinzanetant can play a role in sleep disturbances because of VMS, emerging data on the subject, and how to determine the right candidate for the NK1-3 dual-receptor antagonist.